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A B S T R A C T   
Background and purpose: In rectal cancer patients, radiotherapy in prone position using a belly board can reduce 
the dose to organs at risk. For this patient group we investigated inter-fraction shape variation of the mesorectal 
part of the clinical target volume (CTV) and determined planning target volume (PTV) margins. 
Materials and methods: Patients with rectal cancer receiving neoadjuvant (chemo)radiotherapy were eligible. For 
each patient a planning computed tomography (pCT) and five cone-beam CT (CBCT) scans were acquired in 
prone position using a belly board. The mesorectal CTV was delineated on all scans. Mesorectal shape variation 
was quantified relative to the pCT. PTV margins were derived locally and averaged for separate subregions of the 
mesorectal CTV. For each patient a total PTV was constructed using our clinical margins for mesorectal and 
lymph node CTVs. An artificial dose distribution conforming to this PTV was used to calculate the coverage for 
the mesorectal CTV using the CBCT delineations. 
Results: In 19 rectal cancer patients the derived PTV margins were smallest in the upper-lateral region (6 mm) 
and largest in the upper-anterior region (16 mm). PTV margins for the upper-anterior region were larger for 
female patients (19 mm) compared to male patients (14 mm). Clinical margins for the total PTV were sufficient 
for a coverage of at least 97% of the mesorectal CTV for all patients. 
Conclusions: Mesorectal shape variation is heterogeneous and largest in the upper-anterior region, in rectal cancer 
patients irradiated in prone position and using a belly board.   
1. Introduction 
The standard of surgical resection for rectal cancer consists of total 
mesorectal excision [1–3]. Neoadjuvant radiotherapy (RT) is added for 
primary resectable disease with lymph node involvement or extramural 
invasion >5 mm, resulting in a lower local recurrence rate compared to 
surgery alone [4]. Examples of indications for neoadjuvant chemo-
radiotherapy (CRT) in locally advanced rectal carcinoma are invasion of 
other organs and structures (T4), or T3 with distance to the mesorectal 
fascia (MRF) < 1 mm [5,6]. The most important organs at risk are the 
small bowel and colon (i.e., bowel bag). Multiple studies have shown a 
relationship between the dose to the bowel bag and the incidence of 
intestinal toxicity, such as acute radiation enteritis, chronic diarrhea, 
and less frequently bowel stricture, perforation and hemorrhage [7,8]. 
Bladder filling protocols, prone positioning, and belly boards have been 
used to reduce the volume of bowel in the high-dose region by pushing 
the bowel bag away from the target volume [9,10]. 
In order to reduce the dose to the organs at risk without decreasing 
the target coverage, advanced irradiation techniques such as volumetric 
modulated arc therapy (VMAT) have been developed [11,12]. When 
performing RT with highly conformal VMAT plans, it is important to use 
optimal clinical target volume (CTV) to planning target volume (PTV) 
margins. These margins account for uncertainties in patient setup and 
organ motion/shape variation. In the mesorectal part of the CTV, shape 
variation is known to be substantial and heterogeneous [13,14]. In 
previous studies a large variety of required PTV margins was suggested, 
especially in the upper region of the mesorectum, ranging from 7 to 31 
mm in anterior direction [13–20]. However, to our knowledge, PTV 
margins larger than 20 mm in clinical practice is uncommon in most 
treatment centers. PTV margins described in literature are mainly based 
on studies in which patients were irradiated either in supine or prone 
position without the use of a belly board [14,16–20]. 
The purpose of this study was to investigate the inter-fraction shape 
variation of the mesorectum and determine required PTV margins in 
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rectal cancer patients irradiated in prone position using a belly board. 
2. Materials and methods 
2.1. Patients, scans and treatments 
A total of 20 patients (ten neoadjuvant RT and ten neoadjuvant CRT 
patients, five male and five female each) treated between June 2017 and 
October 2018 were retrospectively selected for this institutional review 
board exempt study. One patient was excluded from the analysis 
because of excessive scatter artefacts on cone-beam CT (CBCT). Baseline 
patient and treatment characteristics are listed in Table 1. Male and 
female patient groups were comparable regarding tumor location, TNM 
stage, MRF involvement and age at diagnosis (data not shown). For one 
of the remaining 19 patients, one CBCT scan was missing. 
A computed tomography (CT) scan with 3 mm slice spacing was 
obtained for treatment planning, ranging from the L2–L3 junction to 
below the perineum. No intravenous, oral or rectal contrast was used. 
Patients were positioned in prone position using a belly board (Macro-
Medics, Waddinxveen, The Netherlands). For all patients a kilovoltage- 
CBCT scan was acquired before each fraction. For neoadjuvant RT pa-
tients (5×5 Gy) all CBCT scans were collected. For neoadjuvant CRT 
patients (25×2 Gy) five out of 25 CBCT scans were collected, one per 
week, randomly. All patients received instructions to drink 500 ml of 
water one hour before the planning CT (pCT) scan and every fraction, 
according to our full bladder protocol. No protocol regarding rectal 
filling/emptying was used. 
2.2. Delineations 
On each pCT and CBCT scan the mesorectal part of the CTV was 
delineated (Fig. 1); no contrast CT nor MRI were used. The anterior, 
posterior and lateral borders of the mesorectum were defined by the 
mesorectal fascia, pelvic muscles and sacrum. To compare both upper 
and lower mesorectal shape variation, the mesorectum was delineated 
along the entire craniocaudal axis, ranging from the anorectal junction 
up to the rectosigmoid junction. The anorectal junction was defined at 
the level of the insertion of the levator ani muscle into the external 
sphincter muscles (i.e., disappearing of the mesorectal fat around the 
rectum) [21]. The rectosigmoid junction was defined using the sigmoid 
take-off as an anatomical landmark [22]. A horizontal line through the 
apex of the os sacrum was used to divide upper and lower mesorectum. 
The lymph nodes regions of the CTV were delineated on each pCT scan 
according to international consensus guidelines [21]. The CBCT scans 
were registered to the pCT scan on bony anatomy (converted to trans-
lations only) in XVI (Elekta, Crawley, UK). Then, the CBCT delineations 
were performed in the treatment planning system (TPS) Pinnacle (Phi-
lips Medical Systems, Fitchburg, USA). During delineation on the CBCT 
scan, the pCT delineation was available to guide the observer. All scans 
were delineated by one observer and evaluated by at least one experi-
enced radiation oncologist. 
2.3. Mesorectal shape variation 
The analysis of mesorectal shape variation was similar to the method 
described by Nijkamp et al. [17]. The mesorectum delineations of all 
scans were interpolated along the craniocaudal axis to 50 slices, inde-
pendent on the length of the mesorectum. On each slice, 100 equidistant 
points were placed, starting at the posterior side of the patient via left, 
anterior, right and back to posterior. As the first point on each slice, the 
point closest to the midline between the leftmost and rightmost point at 
the posterior side was chosen. This is a reproducible anatomical point, 
giving a consistent distribution of the 100 points between slices. For 
each of the 50 × 100 points of each CBCT scan, the signed 1D distance in 
lateral (x) or anterior-posterior (y) direction was calculated between 
corresponding points on the pCT and the CBCT delineations. For points 
on the left/right side the distance was measured in lateral (x) direction 
and for the anterior/posterior side in anterior-posterior (y) direction; the 
subdivision of the 50 × 100 points in anterior, left, posterior and right 
subregions is indicated in Fig. 2. For each patient the mean and standard 
deviation (SD) were calculated over the five CBCT scans for each point 
and stored in 2D surface maps. Subsequently, the local group mean 
(GM), systematic (
∑
) and random error (σ) maps of the total group were 
calculated by the mean of the means, the SD over the means, and the 
root-mean-square of the SDs, respectively. The local means were 
checked for normality (Lilliefors test, significance level p < 0.05). The 
local GM was defined positive when the mean of the means of the CBCT 
positions was distal (in x direction for left/right and in y direction for 
anterior/posterior) to the CT position and negative otherwise. Data 
analyses were performed using Matlab (MathWorks, Natick, USA). 
2.4. PTV margins 
To derive PTV margins mPTV for the mesorectum, we used the recipe 
of Nijkamp et al. [14], i.e., mPTV = α 
∑
+ β √(σ2 + σp) – β σp + GM. 
∑
and σ are the SDs of the systematic and random errors, respectively; σp is 
the SD describing the penumbra (σp = 3.2 mm, corresponding to water 
and suitable for the pelvic region). The additional term GM was added 
by Nijkamp et al. [14] to the original formula of van Herk et al. [23] to 
include deformations, taking the margin direction into account. To 
ensure a minimum CTV dose of 95% of the prescribed dose for at least 
90% of the patients, α = 2.15 and β = 1.64 were used; note that α was 
different from the mostly used value of 2.5, because here the margins 
were effectively analyzed in 2D [23]. 
2.5. Statistical analysis 
Four different groups were compared, being male vs. female, and RT 
vs. CRT patients. For the GM and the σ maps, comparison between 
groups was done using the Wilcoxon rank sum test. The 
∑
maps were 
compared between groups using a two-sided F-test. For all comparisons 
Table 1 
Patient and treatment characteristics.  
Sex (n)  
Male 10 
Female 9 
Age at diagnosis (years)  
Median 65 
Range 39–88 
Treatment (n)  
5x5 Gy male 5 
5x5 Gy female 5 
25x2 Gy male 5 
25x2 Gy female 4 











M-stage (n)  
M0 17 
M1 2 
MRF involvement (n)  
No 10 
Yes 9 
Tumor location (n)  
Proximal (0–5 cm) 6 
Mid-rectal (5–10 cm) 8 
Distal (10–15 cm) 5  
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statistical significance level was set to p < 0.05. 
2.6. Dose coverage 
A simulation was performed to test if the total PTV, based on the 
mesorectal and lymph node CTVs and the clinically used PTV margins, 
was sufficient for the mesorectal shape variation throughout treatment. 
For each patient a total PTV was constructed using the clinical margins 
for the mesorectal CTV (15 mm in anterior direction and 10 mm in all 
other directions) and the clinical margins for the lymph node regions 
(10 mm in all directions). Then, an approximation of an ideal dose 
distribution was created where the 95% isodose surface enclosed the 
total PTV. This was done by expanding the total PTV by β σp = 1.64 ×
3.2 mm = 5.2 mm in three dimensions in the TPS and then convolving 
the resulting 3D surface with a 3D Gaussian with σp = 3.2 mm. Finally, 
for each patient, the dose was sampled in this ideal dose distribution for 
all 50 × 100 points of the mesorectal CTV delineated on each CBCT scan, 
and summed per point to get the cumulative dose on the mesorectal 
CTV. The dose coverage of the mesorectal CTV was calculated as the 
percentage of points with a dose ≥ 95% of the prescription dose. 
3. Results 
The null hypothesis for normality for the local 50 × 100 mean values 
over the total patient group was not rejected for the majority of points 
(84%). GM variation in the whole patient group was relatively small, 
ranging between − 1 mm in the anterior region and 3 mm in the lower- 
posterior region (Fig. 2). 
∑
and σ were ranging from 2 mm in the upper- 
lateral region up to 5 mm in the upper-anterior region. For the whole 
group, there was no significant difference for GM, 
∑
and σ between the 
left and right region; therefore, left and right were combined to “lateral” 
for further statistical analysis. The only significant differences found 
were between male and female patients for the GM of the lower-lateral 
subregions of 1.8 mm and between RT and CRT patients for σ of the 
anterior region of approximately 1.1 mm. 
Derived PTV margins were smallest in the upper-lateral region (6 
mm) and largest in the upper-anterior region (16 mm), as depicted in 
Fig. 2. Differences between subgroups larger than 3 mm were found for 
the PTV margins for the upper-anterior region, which were larger for 
female (19 mm) compared to male patients (14 mm). Margins were 
comparable between RT and CRT patients (Table 2). For the whole 
group of patients for the whole length of the mesorectal CTV, the mar-
gins for mesorectal shape variations were on average 13 mm anteriorly, 
10 mm posteriorly and 7–8 mm laterally (Fig. 2). The dose coverage was 
better than 99% for all patients but one, where coverage was 97%. 
4. Discussion 
The current study showed that mesorectal shape variation is het-
erogeneous, in rectal cancer patients irradiated in prone position using a 
belly board. Our clinical margins for the total PTV were sufficient to 
encompass mesorectal shape variations. 
Literature focusing on inter-fraction mesorectal shape variation in 
rectal cancer irradiation is scarce. In most studies patients were irradi-
ated either in supine position or prone position without using a belly 
board [14,16–20]. Tournel et al. described mesorectal shape variation in 
ten CRT patients placed in prone position without use of a belly board, 
with daily CT scanning [19]. A mean mesorectal shift of − 2 mm (1SD =
6.8 mm) and − 0.4 mm (1SD = 3.8 mm) was found in anterior and 
posterior direction, respectively. However, these results were averaged 
over the craniocaudal axis and over all patients, ignoring the hetero-
geneity of shape variation and the influence of gender. Nijkamp et al. 
evaluated CTV motion for 63 rectal cancer patients in supine position 
using repeat CT imaging [14]. The random error was found 4–7 mm, 
which is in line with our results. Systematic errors were ranging from 2 
mm close to bony structures up to 10 mm at the upper-anterior part of 
Fig. 1. Delineation of the mesorectal part of the CTV on pCT (A, C) and CBCT (B, D) for a female patient. Both transversal (A, B) and sagittal view (C, D) are shown. 
White and black lines indicate the target delineation according to pCT and CBCT, respectively. 
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the mesorectum. In our study a maximum systematic error of 6 mm at 
the upper-anterior region was found in the female patient group (data 
not shown). This difference in maximum systematic error might be 
explained by the use of a belly board, different bladder filling protocols, 
variation in target delineation and/or tumor location. Cranmer-Sargison 
et al. described a PTV margin evaluation for 24 rectal cancer patients 
irradiated in prone position using a belly board. The overall difference in 
mean CTV position was 1.1 mm (1SD = 0.4 mm) and 0.0 mm (1SD = 0.2 
mm) in anterior-posterior and left–right direction, respectively. They 
used 3D bony anatomy matching between pCT and CBCT as a surrogate 
for inter-fractional CTV positional errors. Therefore, they assumed an 
equivalence between CTV and pelvic bony structure position. However, 
Fig. 2. Local group mean (GM), systematic- (
∑
), random error (σ) and PTV margin for the total group of patients. The horizontal axis represents the 100 equidistant 
points of each slice starting at posterior (P), via left (L), anterior (A), right (R) and back to posterior. The vertical axis represents the 50 slices ordered from cranial to 
caudal. The horizontal line indicates the mean slice number of the apex of the os sacrum. The bold numbers in parentheses at the bottom represent the combined 
outcomes of the upper and lower mesorectum for each direction. 
Table 2 
PTV margins (in mm) according to gender and radiotherapy course.   
Male Female  
Anterior Posterior Left Right Anterior Posterior Left Right 
Upper mesorectum 14 7 5 4 19 8 8 7 
Lower mesorectum 8 12 7 7 8 14 10 10 
Total mesorectum 11 9 6 5 14 11 9 8   
5 × 5 Gy 25 × 2 Gy  
Anterior Posterior Left Right Anterior Posterior Left Right 
Upper mesorectum 15 9 7 6 17 6 6 5 
Lower mesorectum 8 15 10 9 9 12 7 8 
Total mesorectum 12 12 8 8 14 9 6 6 
The apex of the os sacrum was chosen as anatomical border to divide upper and lower mesorectum. 
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this is not the case for mesorectal shape variation in anterior direction, 
as the MRF there is not confined by pelvis muscle/bone. This approach 
may result in an underestimation of actual inter-fraction CTV shape 
variation, especially regarding the mesorectum in anterior direction. 
In order to calculate PTV margins, the margin recipe of Nijkamp et al. 
was adapted to a 2D situation [14]. According to van Herk et al., we used 
α = 2.15 for the impact of systematic errors [23]. Multiple values have 
been used for α, for example α = 1.96 and α = 3.2, which apply to a 1D 
and 3D situation, respectively. As a result of this, PTV margins derived 
by Nijkamp et al. (α = 3.2) were larger compared to our margins [14]. 
Cranmer-Sargison et al. used α = 1.96 with PTV margins of 7.0 mm in 
anterior-posterior and 5.0 mm in left–right direction, including correc-
tion for intra-fractional CTV motion up to 3.0 mm [15]. In anterior di-
rection, our current PTV margin for the mesorectal CTV is 15 mm along 
the entire craniocaudal axis. For the lower mesorectum we calculated a 
(average) margin of 9 mm in anterior direction, which was comparable 
for male and female patients. Therefore, it seems safe to reduce the PTV 
margin for the lower-anterior region to 10 mm. The calculated margin 
for the upper-anterior region was larger in the female patient group (19 
mm) compared to the male patient group (14 mm). Minimal differences 
in GM, 
∑
or σ (maximum 1 mm SD) were found between both groups. It 
is probably the combination of these three components in the margin 
recipe that accounts for the larger PTV margin in the female patient 
group. These results are in line with Nijkamp et al., who also suggested 
larger margins are required in the upper-anterior region for female pa-
tients treated in prone position [17]. This can possibly be explained by 
gender-related differences in anatomy. MRI-based studies in patients 
with cervical cancer demonstrated that the uterus shape and position 
can change several centimeters from day-to-day [24,25]. 
PTV margins for the mesorectal CTV in this study were developed 
based on averages of the local margins in several regions. As a conse-
quence, the coverage of the mesorectal CTV will only be correct for the 
average of all points and certain parts of the CTV will be underdosed. To 
get 95% minimum dose for the mesorectal CTV, the maximum value of 
each region should be used, resulting in very large margins. However, 
clinically, those large margins are not used to our knowledge. In rectal 
cancer radiotherapy also the lymph node regions have to be irradiated 
[21]. When the lymph node regions were included in the total PTV, the 
resulting PTV was large enough to “buffer” the shape variations of the 
mesorectum, although the margins of the mesorectal CTV on its own 
were in principle to small for the entire mesorectum. This could be 
shown using an approximation of an ideal dose distribution. 
This study had several limitations. First, the nodal subregions of the 
CTV were not delineated, because low inter-fraction shape variation was 
expected and these structures are difficult to delineate on low resolution 
CBCT scans. Nijkamp et al. are the only group that investigated shape 
variation of the internal iliac, obturatorial and presacral lymph node 
regions, describing PTV margins ranging from 7 mm in posterior di-
rection to 15 mm in anterior direction [14]. Second, mesorectal shape 
variation was assessed in a 2D situation and was not evaluated in cra-
niocaudal direction. Third, delineation variation, intra-fraction setup 
errors and intra-fraction mesorectal shape variation were not investi-
gated and thus not included in the margin calculation. Delineation 
variation was minimized by having one observer for all patients, avail-
ability of the pCT delineations during CBCT delineation, and evaluation 
of all delineations together with one of the two selected radiation on-
cologists. Because of the time scale, intra-fraction mesorectal shape 
variations are not larger than the inter-fraction variations, and were thus 
indirectly taken care of in our analysis. Whereas inter-fraction setup 
errors were addressed by online corrections based on bony anatomy, 
intra-fraction errors also contribute to the overall uncertainty. Nijkamp 
et al. reported intra-fraction setup errors up to 2.4 mm in left–right di-
rection, regarding prone positioning without belly board [17]. Also 
other uncertainties, such as registration uncertainties, residual rota-
tions, accelerator-related mechanical uncertainties should be taken into 
account in the total PTV margins. As this is a complex process, end-to- 
end tests can be used for estimates [26]; due to their size in the order 
of millimeters, the impact of these uncertainties is limited. 
In conclusion, this study demonstrated that mesorectal shape varia-
tion is heterogeneous and largest in the upper-anterior region, in rectal 
cancer patients irradiated in prone position with the use of a belly board. 
Calculated PTV margins were ranging from 6 mm in the upper-lateral 
region up to 16 mm in the upper-anterior region of the mesorectum. 
Subgroup analysis revealed that a larger PTV margin in the upper- 
anterior region is needed for female patients compared to male pa-
tients. In literature, a large variety of PTV margins has been reported for 
both prone and supine positioning, especially in the anterior direction. 
Therefore, it remains important to determine institutional PTV margins 
depending on patient positioning, radiation technique and online 
imaging. 
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[11] Dröge LH, Weber HE, Guhlich M, Leu M, Conradi L-C, Gaedcke J, et al. Reduced 
toxicity in the treatment of locally advanced rectal cancer: a comparison of 
volumetric modulated arc therapy and 3D conformal radiotherapy. BMC Cancer 
2015;15. https://doi.org/10.1186/s12885-015-1812-x. 
[12] Wee CW, Kang HC, Wu HG, Chie EK, Choi N, Park JM, et al. Intensity-modulated 
radiotherapy versus three-dimensional conformal radiotherapy in rectal cancer 
treated with neoadjuvant concurrent chemoradiation: a meta-analysis and pooled- 
analysis of acute toxicity. Jpn J Clin Oncol. 2018;48:458-66. https://doi.org/ 
10.1093/jjco/hyy029. 
[13] Nuyttens JJ, Robertson JM, Yan Di, Martinez A. The variability of the clinical 
target volume for rectal cancer due to internal organ motion during adjuvant 
treatment. Int J Radiat Oncol Biol Phys 2002;53:497–503. https://doi.org/ 
10.1016/S0360-3016(02)02753-0. 
M.C. Cox et al.                                                                                                                                                                                                                                  
Physics and Imaging in Radiation Oncology 19 (2021) 120–125
125
[14] Nijkamp J, Swellengrebel M, Hollmann B, de Jong R, Marijnen C, van Vliet- 
Vroegindeweij C, et al. Repeat CT assessed CTV variation and PTV margins for 
short- and long-course pre-operative RT of rectal cancer. Radiother Oncol 2012; 
102:399–405. https://doi.org/10.1016/j.radonc.2011.11.011. 
[15] Cranmer-Sargison G, Kundapur V, Park-Somers E, Andreas J, Vachhrajani H, 
Sidhu NP. Planning target volume margin evaluation and critical structure sparing 
for rectal cancer patients treated prone on a bellyboard. Clin Oncol (R Coll Radiol) 
2013;25:e17–22. https://doi.org/10.1016/j.clon.2012.08.001. 
[16] Brierley JD, Dawson LA, Sampson E, Bayley A, Scott S, Moseley JL, et al. Rectal 
motion in patients receiving preoperative radiotherapy for carcinoma of the 
rectum. Int J Radiat Oncol Biol Phys 2011;80:97–102. https://doi.org/10.1016/j. 
ijrobp.2010.01.042. 
[17] Nijkamp J, de Jong R, Sonke J-J, Remeijer P, van Vliet C, Marijnen C. Target 
volume shape variation during hypo-fractionated preoperative irradiation of rectal 
cancer patients. Radiother Oncol 2009;92:202–9. https://doi.org/10.1016/j. 
radonc.2009.04.022. 
[18] Bondar L, Intven M, Burbach JP, Budiarto E, Kleijnen JP, Philippens M, et al. 
Statistical modeling of CTV motion and deformation for IMRT of early-stage rectal 
cancer. Int J Radiat Oncol Biol Phys 2014;90:664–72. https://doi.org/10.1016/j. 
ijrobp.2014.06.040. 
[19] Tournel K, De Ridder M, Engels B, Bijdekerke P, Fierens Y, Duchateau M, et al. 
Assessment of intrafractional movement and internal motion in radiotherapy of 
rectal cancer using megavoltage computed tomography. Int J Radiat Oncol Biol 
Phys 2008;71:934–9. https://doi.org/10.1016/j.ijrobp.2008.02.032. 
[20] Nijkamp J, de Jong R, Sonke J-J, van Vliet C, Marijnen C. Target volume shape 
variation during irradiation of rectal cancer patients in supine position: comparison 
with prone position. Radiother Oncol 2009;93:285–92. https://doi.org/10.1016/j. 
radonc.2009.08.007. 
[21] Valentini V, Gambacorta MA, Barbaro B, Chiloiro G, Coco C, Das P, et al. 
International consensus guidelines on Clinical Target Volume delineation in rectal 
cancer. Radiother Oncol 2016;120:195–201. https://doi.org/10.1016/j. 
radonc.2016.07.017. 
[22] D’Souza N, de Neree tot Babberich MPM, Lord A, Shaw A, Abulafi M, Tekkis P, 
et al. The rectosigmoid problem. Surg Oncol 2018;27:521–5. https://doi.org/ 
10.1016/j.suronc.2018.06.005. 
[23] van Herk M, Remeijer P, Rasch C, Lebesque JV. The probability of correct target 
dosage: dose-population histograms for deriving treatment margins in 
radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:1121–35. https://doi.org/ 
10.1016/S0360-3016(00)00518-6. 
[24] Taylor A, Powell ME. An assessment of interfractional uterine and cervical motion: 
implications for radiotherapy target volume definition in gynaecological cancer. 
Radiother Oncol 2008;8:250–7. https://doi.org/10.1016/j.radonc.2008.04.016. 
[25] van de Bunt L, Jürgenliemk-Schulz IM, de Kort GAP, Roesink JM, Tersteeg RJHA, 
van der Heide UA. Motion and deformation of the target volumes during IMRT for 
cervical cancer: what margins do we need? Radiother Oncol 2008;88:233–40. 
https://doi.org/10.1016/j.radonc.2007.12.017. 
[26] Seravalli E, van Haaren PMA, van der Toorn PP, Hurkmans CW. A comprehensive 
evaluation of treatment accuracy, including end-to-end tests and clinical data, 
applied to intracranial stereotactic radiotherapy. Radiother Oncol 2015;116: 
131–8. https://doi.org/10.1016/j.radonc.2015.06.004. 
M.C. Cox et al.                                                                                                                                                                                                                                  
